Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BMRN | 8-K | neutral | 4/10 | BioMarin discontinued development of VOXZOGO for Noonan syndrome, citing feasibility and the current treatment landscape | Sep 15, 2026 |
| SMMT | 8-K | bullish | 7/10 | Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + | Sep 15, 2026 |
| MAIA | CLUSTER | bullish | 6/10 | CEO Vlad Vitoc and Director Ramiro Guerrero collectively purchased $150K of MAIA stock in open-market transactions over | Sep 15, 2026 |
| GTBP | 8-K | bearish | 7/10 | GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Prefer | Sep 15, 2026 |
| MSLE | 6-K | neutral | 3/10 | Satellos announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, | Sep 15, 2026 |
| MAIA | PRESS-RELEASE | bullish | 5/10 | MAIA Biotechnology announced insider purchases totaling ~$325K by a board member and the CEO, signaling management confi | Sep 15, 2026 |
| CNTB | 8-K | mixed | 6/10 | Connect Biopharma reported positive preliminary Phase 2 topline data for rademikibart as an add-on treatment for acute a | Sep 15, 2026 |
| RCKT | 8-K | bullish | 7/10 | Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 for Danon di | Sep 15, 2026 |
| BIVI | PRESS-RELEASE | mixed | 6/10 | BioVie announced topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID. The study failed to achieve stat | Sep 15, 2026 |
| FBLG | 8-K | neutral | 4/10 | FibroBiologics entered into a securities purchase agreement with its Chief Scientific Officer, Hamid Khoja, to sell 298, | Sep 15, 2026 |
| BRNS | EFFECT | neutral | 4/10 | Barinthus Biotherapeutics plc's registration statement has become effective, allowing the company to proceed with its se | Sep 15, 2026 |
| NVO | 6-K | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. The filing is a Form 6-K submitted by Novo Nor | Sep 15, 2026 |
| GSK | 6-K | neutral | 5/10 | GSK announced an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma fr | Sep 15, 2026 |
| SAFX | S-3 | bearish | 8/10 | XCF Global filed a $300M universal shelf registration (S-3) on September 14, 2026, including a $100M at-the-market (ATM) | Sep 15, 2026 |
| SAFX | 425 | mixed | 7/10 | XCF Global, DevvStream, and Southern Energy Renewables amended their Business Combination Agreement, increasing XCF shar | Sep 15, 2026 |
| SLGL | INSIDER-BUY | bullish | 6/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, has been aggressively buying shares on the open market, to | Sep 15, 2026 |
| AMLX | CLUSTER | mixed | 4/10 | Two C-suite insiders at Amylyx (CFO and CMO) sold a combined ~$103K in open-market sales on September 10, 2026, just two | Sep 15, 2026 |
| ARTV | CLUSTER | neutral | 4/10 | Four Artiva Biotherapeutics insiders, including the CEO, COO, CTO, and CMO, sold a total of $477K in open-market shares | Sep 15, 2026 |
| ARTV | CLUSTER | neutral | 3/10 | Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over | Sep 14, 2026 |
| ANIP | CLUSTER | neutral | 2/10 | Two ANIP insiders, a director and the SVP/General Counsel, sold a combined $107K in open-market transactions over a 4-da | Sep 14, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | A stipulated protective order was entered in Rapacon v. Abbott Laboratories, a routine procedural step governing the han | Sep 14, 2026 |
| IBIO | 8-K | neutral | 4/10 | iBio filed an updated corporate presentation (Ex-99.1) under Items 7.01 and 8.01, highlighting its pipeline of next-gene | Sep 14, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines executed a cluster of open-market sales totaling ~$6.5M over three days, with the b | Sep 14, 2026 |
| ARTV | CLUSTER | neutral | 4/10 | A cluster of insider selling at Artiva Biotherapeutics (ARTV) totaling $477K over the past week, led by CEO Fred Aslan ( | Sep 14, 2026 |
| JAZZ | CLUSTER | neutral | 3/10 | Two Jazz Pharmaceuticals insiders, including the President & CEO and EVP & Chief Legal Officer, sold a combined $775K in | Sep 14, 2026 |
| BHST | 6-K | neutral | 2/10 | BioHarvest Sciences announced that CEO Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conf | Sep 14, 2026 |
| LGVN | 8-K | bullish | 5/10 | Longeveron received written notification from Nasdaq on September 11, 2026, confirming that its Class A common stock had | Sep 14, 2026 |
| AGMB | 6-K | bullish | 7/10 | No summary provided | Sep 14, 2026 |
| PHVS | 144 | neutral | 2/10 | Director Berndt Modig filed a Form 144 to sell 2,291 common shares (approx. $87K) on September 14, 2026. The shares were | Sep 14, 2026 |
| RYTM | 144 | bearish | 5/10 | David Meeker, a director and officer of Rhythm Pharmaceuticals, filed a Form 144 notice of intent to sell 50,000 shares | Sep 14, 2026 |